NIH GUIDE, Volume 24, Number 30, August 18, 1995




National Cancer Institute

The Drug Synthesis and Chemistry Branch (DS&CB), Developmental

Therapeutics Program (DTP), Division of Cancer Treatment (DCT) of the

National Cancer Institute (NCI) is seeking contractors with expertise

in chemical synthesis and drug design to synthesize a variety of

compounds for evaluation as potential anti-cancer and anti-HIV

agents.  The assigned objectives of this project are to design and

synthesize the following:  (a) congeners of lead compounds having

confirmed activity to enhance activity or potency; (b) prodrugs with

structural modifications that may provide altered pharmacokinetics,

altered drug transport, improved bio-availability through increased

water solubility or increased chemical stability; (c) other altered

structures that possess elements of both congener and prodrug; and

(d) compounds related to natural products, e.g., alkaloids,

heterocycles, nucleosides, peptides and the like.  Each contractor

must have available a fully operational facility including all

necessary equipment and instrumentation for all aspects of the


The nature of this project requires that the following restriction be

applied:  "The NCI signs legally binding agreements with certain

suppliers (often pharmaceutical or chemical companies) which state

that all information on compounds submitted by the supplier will be

held confidential."  The successful offeror will be expected to

synthetically modify such commercially confidential (discreet)

materials.  Thus, pharmaceutical or chemical companies could obtain

valuable data on new lead compounds.  Therefore, in order to honor

the confidentiality agreement with the original supplier, the NCI

believes that the compounds cannot be sent to potential competitors

of the supplier, and thus pharmaceutical and chemical companies must

be excluded from the competition.  The intent of the exclusion is to

prevent companies who market chemicals or drugs on the open market

from gaining undue competitive advantage by access to privileged

inside information.  The exclusion does not apply to companies and/or

laboratories whose synthesis activities are performed on a specific

order from another party.  It is understood that such companies do

not sell drugs or chemicals on the open market and are thus not in a

position to profit from access to privileged information from NCI.

It is anticipated that 6,032 hours per award per year will be

required for this project.  This is a recompetition of contracts

currently held by the Purdue Research Foundation (N01-CM-17512),

Research Foundation of the State University of New York at Buffalo

(N01-CM-17569), Georgia Tech Research Foundation (N01-CM-17570) and

(N01-CM-47012), and University of Tennessee (N01-CM-47038).  It is

anticipated that four cost-reimbursement contracts will be awarded

for a period of three years, with two one-year options, beginning on

or about August 1, 1996.


Requests for RFP No. NCI-CM-67246-74 may be directed to:

Odessa Henderson

Research Contracts Branch

National Cancer Institute

6120 Executive Boulevard, Suite 603

Rockville, MD  20892

Telephone:  (301) 496-8620

No collect calls will be accepted.


Return to 1995 Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.